Dr Suzette Anne Woodward, MD | |
2620 W Faidley Ave, Grand Island, NE 68803-4205 | |
(308) 398-5424 | |
(308) 398-5429 |
Full Name | Dr Suzette Anne Woodward |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 2620 W Faidley Ave, Grand Island, Nebraska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215972047 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 20561 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Suzette Anne Woodward, MD 2407 Cottonwood Rd, Grand Island, NE 68801-7563 Ph: (308) 381-4377 | Dr Suzette Anne Woodward, MD 2620 W Faidley Ave, Grand Island, NE 68803-4205 Ph: (308) 398-5424 |
News Archive
The largest-ever study of treatments for diabetes has shown that a fixed combination of two blood pressure lowering drugs reduces the risk of death, as well as the risks of heart and kidney disease. Results from the ADVANCE (Action in Diabetes and Vascular Disease) Study were presented today at the European Society of Cardiology Congress 2007 in Vienna.
The average monthly emergency department visit increased by 5.7 percent in Illinois after the implementation of the Affordable Care Act, although the population remained essentially flat.
Adding hormone therapy to radiation therapy has been proven in randomized clinical trials to improve overall survival for men with intermediate- and high-risk prostate cancer. However, adding hormone therapy may reduce overall survival in men with pre-existing heart conditions, even if they have high-risk prostate cancer according to a new study just published online in advance of print in the International Journal of Radiation Oncology·Biology·Physics, the official scientific journal of ASTRO.
Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
› Verified 2 days ago
Dr. Kris L Mleczko, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2620 W Faidley Ave, St. Francis Med. Ctr., Grand Island, NE 68803 Phone: 308-398-5424 Fax: 308-398-5429 | |
Dr. Scott Alan Frankforter, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 2620 W Faidley Ave, Grand Island, NE 68803 Phone: 308-398-5424 Fax: 308-398-5429 | |
Dr. Brent Wayne Keenportz, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2620 W Faidley Ave, Grand Island, NE 68803 Phone: 308-398-5424 |